Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF4E | P06730 | 10/20 | 0.50 |
| ▸ | SLC22A12 | Q96S37 | 5/20 | 0.43 |
| ▸ | XDH | P47989 | 4/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30792116 | 1.00 | EIF4E (0.50) | EIF4ESLC22A12XDHCASP1PIN1 | |
| SCHEMBL31015721 | 0.91 | EIF4E (0.49) | EIF4ESLC22A12XDHCASP1PIN1 | |
| SCHEMBL27307967 | 0.88 | SLC22A12 (0.48) | EIF4ESLC22A12XDHPIN1KDM4C | |
| SCHEMBL31319310 | 0.87 | EIF4E (0.43) | EIF4ESLC22A12XDHCASP1HSD17B10 | |
| SCHEMBL24820114 | 0.83 | KDM4E (0.43) | EIF4ECASP1PPARG | |
| SCHEMBL3818624 | 0.82 | EIF4E (0.52) | EIF4ESLC22A12XDHCASP1HSD17B10 | |
| SCHEMBL24820734 | 0.81 | ALDH1A1 (0.53) | EIF4ECASP1HSD17B10 | |
| SCHEMBL30792148 | 0.81 | ALDH1A1 (0.53) | EIF4ECASP1HSD17B10 | |
| SCHEMBL31015643 | 0.80 | ADORA2A (0.45) | EIF4ECASP1KDM4CPPARG | |
| SCHEMBL20520098 | 0.80 | FOLH1 (0.53) | EIF4ESLC22A12XDHHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116868-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2026-04-30 | — | — | US | disclosed |
| WO-2025076299-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2025-04-10 | — | — | WO | disclosed |
| US-20250011318-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2025-01-09 | — | — | US | disclosed |
| CN-117858865-A | CBL-B modulators and uses thereof | 林伯士克莱奥公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-117858707-A | CBL-B modulators and uses thereof | 林伯士克莱奥公司 | 2024-04-09 | — | — | CN | disclosed |
| WO-2024062363-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS CBL-B INHIBITORS | GLENMARK PHARMACEUTICALS LTD (IN) | 2024-03-28 | — | — | WO | disclosed |
| WO-2022272248-A1 | CBL-B MODULATORS AND USES THEREOF | NIMBUS CLIO, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260116868-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | CBLB, CBLC, CBL | EIF4E 2584/4885SLC22A12 3160/4885XDH 4113/4885 |
| US-20250011318-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | CBLB, CBL, CBLC | EIF4E 2098/4885SLC22A12 2983/4885XDH 2906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.